Diagnosis and management of eosinophilic asthma: a US perspective.
Diagnosis and management of eosinophilic asthma: a US perspective.
复制标题
DOI：
10.2147/jaa.s39119
复制
发表时间：
2014
影响因子：
3.2
通讯作者：
Doherty TA
中科院分区：
文献类型：
--
作者：
Walford HH;Doherty TA
嗜酸性哮喘是目前公认的一种重要的哮喘亚型，其基础是炎性细胞在呼吸道的浸润型。嗜酸性哮喘可与哮喘严重程度增加、特应性、迟发性疾病和类固醇耐受性有关。诱导痰细胞计数是识别哮喘嗜酸性炎症的金标准，尽管几种非侵入性生物标志物，包括部分呼出的一氧化氮和Periostin，正在成为潜在的替代品。随着新的治疗方法和生物制剂的日益可用，对特定的表型导向治疗策略的需求也越来越大。更好地认识和理解这种哮喘表型的独特免疫病理学对疾病的管理和改善患者预后的潜力具有重要意义。本文就嗜酸粒细胞哮喘的临床特点、发病机制、诊断和治疗进行综述。
Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and steroid refractoriness. Induced sputum cell count is the gold standard for identifying eosinophilic inflammation in asthma although several noninvasive biomarkers, including fractional exhaled nitric oxide and periostin, are emerging as potential surrogates. As novel therapies and biologic agents become increasingly available, there is an increased need for specific phenotype-directed treatment strategies. Greater recognition and understanding of the unique immunopathology of this asthma phenotype has important implications for management of the disease and the potential to improve patient outcomes. The present review provides a summary of the clinical features, pathogenesis, diagnosis, and management of eosinophilic asthma.